Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lirilumab · IPH2102, BMS-986015

Monoclonal antibody · Antagonist of Killer-cell immunoglobulin-like receptors (KIR) · developed by Bristol-Myers Squibb

Phase 2 Most advanced trial (none active)
1 Registered trials

What is Lirilumab?

Lirilumab is a fully human monoclonal antibody that binds killer-cell immunoglobulin-like receptors (KIR) on natural killer cells, preventing KIR ligands from binding and thereby blocking these inhibitory receptors. It is being studied in acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IPH2102, BMS-986015, BMS-986015-01
Drug type
Monoclonal antibody
Targets
Killer-cell immunoglobulin-like receptors (KIR)
Mechanism
Antagonist of Killer-cell immunoglobulin-like receptors (KIR)
Pathways
NK cell activation
Therapy area
Oncology
Developer
Bristol-Myers Squibb
In trials of
IPHA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
S9XDI9W918

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01687387 Phase 2 Acute Myeloid Leukemia Completed IPHA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid Leukemia

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.